Cardiovascular outcome trials have established benefits for specific agents: the LEADER trial for liraglutide, SUSTAIN-6 for injectable semaglutide, and REWIND for dulaglutide demonstrated reduced risk of major adverse cardiovascular events in patients with type 2 diabetes
LC-MS/MS was performed using an Evosep LC (Evosep Biosystems) connected to a Q Exactive HF (Thermo Fisher Scientific)
GLP-1 mimetic drugs and the risk of exocrine pancreatic disease: Cell and animal studies
In addition, the platform doesn't allow "trading, marketing, or providing access to regulated, prohibited, or high-risk goods and services," or directing users to third-party platforms to acquire such goods
Many supplements are not suitable for certain dietary restrictions, including vegan and vegetarian diets
Joshua Nead| Peter Michiels| Thomas Malone | Darby Kramer